PRIMETIME LIFE SCIENCES, LLC
MRS5474, a small-molecule adenosine A1 receptor agonist therapeutic for rapid-onset depression treatment
- Sector
- Biotech
- Headquarters
- Germantown, MD
- Total capital
- $7.6M
- Federal grants
- $7.6M
- 8 awards · 2018–2025
- Rank in peer group#82 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $79K
- 2 awards · Health and Human S
- Rank in Biotech#339 of 4373
- Granted patents
- 0
- 6 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of PTLS-209 for treatment for giardiasis$1M
- Federal grantHealth and Human S · Phase II · Development of PTLS-209 for treatment for giardiasis$916K
- Federal grantHealth and Human S · Phase II · Development of PTLS-209 for treatment for giardiasis$634K
- Federal grantHealth and Human S · Phase II · Development of PTLS-209 for treatment for giardiasis$300K
- Federal grantHealth and Human S · Phase II · Development of an adenosine A1 receptors agonist, MRS5474 for the treatment of chronic depression$935K
- Federal grantHealth and Human S · Phase II · Development of an adenosine A1 receptors agonist, MRS5474 for the treatment of chronic depression$841K
- Federal grantHealth and Human S · Phase II · Development of an adenosine A1 receptors agonist, MRS5474 for the treatment of chronic depression$2.6M
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase II · Development of an adenosine A1 receptors agonist, MRS5474 for the treatment of chronic depression$350K
- Federal contractHealth and Human S · Igf::ot::igf - Primetime Life Sciences, LLC:1243350 [16-011873]$14K
- Federal contractHealth and Human S · Igf::ot::igf - [14-007010]PRIMETIME Life Sciences, LLC:1243350$65K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#82 · top 16%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 6- PendingInhibitors of methionine aminopeptidase-2 and methods of preparation and uses thereofUSPTOApplication 19103290
- PendingCompounds And Methods For Modulation Of G-protein-coupled ReceptorsUSPTOApplication 17055591
- PendingInhibitors Of Methionine AMINOPEPTIDASE-2 And Methods Of Preparation And Uses ThereofUSPTOApplication PCTUS2023072133
Show all 6 patent records
- Inhibitors of methionine aminopeptidase-2 and methods of preparation and uses thereofJun 18, 2026 · Application 19103290Pending
- Compounds And Methods For Modulation Of G-protein-coupled ReceptorsJan 1, 2026 · Application 17055591Pending
- Inhibitors Of Methionine AMINOPEPTIDASE-2 And Methods Of Preparation And Uses ThereofApplication PCTUS2023072133Pending
- Biguanidine Derivatives Of Therapeutic Agents And Methods Of Preparation And Use ThereofApplication 16641734Pending
- Compounds And Methods For Modulation Of G-protein-coupled ReceptorsApplication PCTUS2019043558Pending
- Biguanidine Derivatives Of Therapeutic Agents And Methods Of Preparation And Use ThereofApplication PCTUS2018049382Pending
Related companies, and why
- FINA BIOSOLUTIONS LLCSimilar federal contract value in Biotech · $83K in contracts
- Celularity IncSimilar federal contract value in Biotech · $80K in contracts
- AUM LIFETECH INCSimilar federal contract value in Biotech · $80K in contracts
- Nexome Genomics Inc.Similar federal contract value in Biotech · $78K in contracts
- ORA BIOMEDICAL, INC.Similar federal contract value in Biotech · $75K in contracts
- Agios PharmaceuticalsSimilar federal contract value in Biotech · $73K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .